Table 1.
Clinical and demographic characteristics of the study cohort.
| RRMS (n = 31) | SPMS (n = 28) | p value | |
|---|---|---|---|
| Age (years,) mean ± SD | 43.5 ± 9.7 | 58.1 ± 9.6 | < 0.001 |
| Female, no. (%) | 23 (74.2) | 20 (71.4) | 0.811 |
| Disease duration (years), median (range) | 9.2 (0.8–24.2) | 26.6 (3.9–50.3) | < 0.001 |
| ARRa last 2 years, median (range) | 0.0 (0.0–1.5) | 0.0 (0.0–0.0) | < 0.001 |
| Time since last relapse (months), median (range) | 23.8 (0.92–142.9) | – | – |
| EDSS, median (range) | 2.5 (1.0–6.5) | 7.0 (4.5–8.5) | < 0.001 |
| DMT use, no. (%) | 20 (64.5) | 0 (0.0) | < 0.001 |
| Glatiramer acetate | 8 (25.8) | – | – |
| Interferon beta | 2 (6.5) | – | – |
| Dimethyl fumarate | 7 (22.6) | – | – |
| Fingolimod | 1 (3.2) | – | – |
| Natalizumab | 1 (3.2) | – | – |
| Alemtuzumab | 1 (3.2) | – | – |
| BMI, mean ± SD | 25.9 ± 4.6 | 28.0 ± 5.9 | 0.132 |
ARR annualised relapse rate, BMI body mass index, DMT disease modifying therapy, EDSS Expanded Disability Status Scale, RRMS relapsing–remitting MS, SD standard deviation, SPMS secondary progressive MS.
aARR calculated only if disease duration is at least 2 years.